JP2020075934A5 - - Google Patents

Download PDF

Info

Publication number
JP2020075934A5
JP2020075934A5 JP2020012396A JP2020012396A JP2020075934A5 JP 2020075934 A5 JP2020075934 A5 JP 2020075934A5 JP 2020012396 A JP2020012396 A JP 2020012396A JP 2020012396 A JP2020012396 A JP 2020012396A JP 2020075934 A5 JP2020075934 A5 JP 2020075934A5
Authority
JP
Japan
Prior art keywords
cancer
seq
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020012396A
Other languages
English (en)
Japanese (ja)
Other versions
JP6956967B2 (ja
JP2020075934A (ja
Filing date
Publication date
Priority claimed from JP2019076826A external-priority patent/JP6713160B2/ja
Application filed filed Critical
Publication of JP2020075934A publication Critical patent/JP2020075934A/ja
Publication of JP2020075934A5 publication Critical patent/JP2020075934A5/ja
Priority to JP2021154508A priority Critical patent/JP7253210B2/ja
Application granted granted Critical
Publication of JP6956967B2 publication Critical patent/JP6956967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020012396A 2015-05-20 2020-01-29 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用 Active JP6956967B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021154508A JP7253210B2 (ja) 2015-05-20 2021-09-22 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015103145 2015-05-20
JP2015103145 2015-05-20
JP2019076826A JP6713160B2 (ja) 2015-05-20 2019-04-15 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019076826A Division JP6713160B2 (ja) 2015-05-20 2019-04-15 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021154508A Division JP7253210B2 (ja) 2015-05-20 2021-09-22 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用

Publications (3)

Publication Number Publication Date
JP2020075934A JP2020075934A (ja) 2020-05-21
JP2020075934A5 true JP2020075934A5 (https=) 2020-07-02
JP6956967B2 JP6956967B2 (ja) 2021-11-02

Family

ID=57320344

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017519401A Active JP6515182B2 (ja) 2015-05-20 2016-05-19 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
JP2019076826A Active JP6713160B2 (ja) 2015-05-20 2019-04-15 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
JP2020012396A Active JP6956967B2 (ja) 2015-05-20 2020-01-29 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
JP2021154508A Active JP7253210B2 (ja) 2015-05-20 2021-09-22 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017519401A Active JP6515182B2 (ja) 2015-05-20 2016-05-19 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
JP2019076826A Active JP6713160B2 (ja) 2015-05-20 2019-04-15 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021154508A Active JP7253210B2 (ja) 2015-05-20 2021-09-22 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用

Country Status (7)

Country Link
US (2) US20180140691A1 (https=)
EP (1) EP3299028B1 (https=)
JP (4) JP6515182B2 (https=)
CN (1) CN107921106B (https=)
CA (1) CA2986367A1 (https=)
ES (1) ES2993462T3 (https=)
WO (1) WO2016186177A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
LT3377516T (lt) * 2015-11-20 2022-09-26 Memorial Sloan Kettering Cancer Center Kompozicija vėžiui gydyti
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
EP3549957A4 (en) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
US12215151B2 (en) 2017-05-31 2025-02-04 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
EP3676616A1 (en) * 2017-08-28 2020-07-08 Bristol-Myers Squibb Company Tim-3 antagonists for the treatment and diagnosis of cancers
WO2019071147A1 (en) * 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
MX2021003660A (es) 2018-09-28 2021-05-28 Sumitomo Pharma Co Ltd Composicion inyectable.
AU2019352354B2 (en) * 2018-10-05 2025-07-03 International Institute Of Cancer Immunology, Inc. Prophylactic or therapeutic drug for benign tumor
CA3136352A1 (en) * 2019-04-10 2020-10-15 Slsg Limited Llc Multi-valent immunotherapy composition and methods of use for treating wt1-positive cancers
US20210030868A1 (en) * 2019-07-29 2021-02-04 Cai Gu Huang Formulation of antibody based drugs for treating lung cancer by inhalation
WO2021117771A1 (ja) 2019-12-10 2021-06-17 大日本住友製薬株式会社 ペプチドエマルション製剤の調製方法
US20230331858A1 (en) * 2019-12-24 2023-10-19 Neoleukin Therapeutics, Inc. Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
EP4149512A4 (en) * 2020-05-12 2024-06-05 Board of Regents, The University of Texas System Methods for treating glioblastoma
EP4149953A4 (en) * 2020-05-12 2024-06-26 Lg Chem, Ltd. MULTIMER T CELL MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
TW202208395A (zh) * 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2021230247A1 (ja) * 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
WO2022030631A1 (ja) * 2020-08-07 2022-02-10 株式会社 メドレックス 組み合わせ製剤
EP4313046A1 (en) * 2021-03-31 2024-02-07 Celleron Therapeutics Limited Vaccine adjuvant
CN117838860B (zh) * 2023-11-27 2025-03-14 四川大学 一种抑制周围神经侵袭的药物、药物组合物、联合用药物
CN119161494B (zh) * 2024-11-18 2025-10-21 北京宝易生物技术有限公司 疫苗稀释液制备方法和应用
CN121015864B (zh) * 2025-10-31 2026-02-03 可蓝赛生物医药(上海)有限公司 一种含有多糖佐剂的肿瘤疫苗及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003300184B8 (en) * 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
EP1584627B1 (en) * 2003-01-15 2009-10-07 International Institute of Cancer Immunology, Inc. Dimerized peptide
WO2004094409A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP1644034B1 (en) * 2003-07-10 2011-01-12 Cytos Biotechnology AG Composition for enhancing an immune response comprising packaged virus-like particles
WO2005037995A2 (en) * 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
JP5427027B2 (ja) * 2006-05-03 2014-02-26 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2744449C (en) * 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
EP3165540A1 (en) * 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
CN103157108B (zh) * 2011-12-13 2016-01-20 宁云山 免疫调节剂组合物及其药物组合物和应用
JP2015501839A (ja) * 2011-12-15 2015-01-19 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN103830211A (zh) * 2012-11-27 2014-06-04 上海曼克尔瑞生物医药技术有限公司 一种β-catenin蛋白抑制剂-姜黄素在肝癌治疗方面的应用
JP6497691B2 (ja) * 2013-02-05 2019-04-10 日東電工株式会社 粘膜投与用ｗｔ１ペプチド癌ワクチン組成物
PT2961831T (pt) * 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
MY171854A (en) * 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
CA2920377A1 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Similar Documents

Publication Publication Date Title
JP2020075934A5 (https=)
JP2013534922A5 (https=)
JP2025160318A5 (https=)
JP2023015291A5 (https=)
CN108699001B (zh) 作为免疫调节剂的杂环化合物
AU2019358948B2 (en) STING Agonistic Compound
DK3041828T3 (en) 1,3,4-OXADIAZOL AND 1,3,4-THIADIAZOLD DERIVATIVES AS IMMUNE MODULATORS
ES2768610T3 (es) Inhibidores macrocíclicos de las interacciones proteína/proteína PD-1/PD-L1 y CD80(B7-1)/PD-L1
ES2904317T3 (es) Dinucleótidos cíclicos como agentes anticancerosos
AU2018271235A1 (en) Cyclic peptidomimetic compounds as immunomodulators
US10973834B2 (en) EP4 inhibitors and use thereof
JP2020506951A5 (https=)
JP2007530526A5 (https=)
KR20200111738A (ko) 면역조정제로서 유용한 2,8-디아실-2,8-디아자스피로[5.5]운데칸 화합물
JP2008544755A5 (https=)
RU2020124007A (ru) Комбинированный препарат, включающий агонист tlr7
RU2018142573A (ru) Партнеры по связыванию lag-3
JP2015534577A5 (https=)
TW201636359A (zh) 免疫調節劑
JP2013544804A5 (https=)
RU2017139515A (ru) Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
JPWO2021177438A5 (https=)
JP2018516994A5 (https=)
JP7296070B2 (ja) がん免疫療法アジュバント
US10744134B2 (en) Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient